Jiangsu Hengrui Pharmaceuticals Co Ltd. Stock Analysis 600276.SS

Jiangsu Hengrui Pharmaceuticals Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Lianyungang, Jiangsu and currently employs 20,602 full-time employees. The company went IPO on 2000-10-18. Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The firm focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The firm's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The firm mainly conducts its businesses in domestic and foreign markets.